Calporta's Series A Round

Calporta raised a round of funding on June 15, 2015.

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and ot…

Articles about Calporta's Series A Round: